24,572 Shares in IVERIC bio, Inc. (NASDAQ:ISEE) Acquired by WINTON GROUP Ltd

WINTON GROUP Ltd acquired a new position in IVERIC bio, Inc. (NASDAQ:ISEEGet Rating) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 24,572 shares of the company’s stock, valued at approximately $236,000.

Several other institutional investors also recently modified their holdings of the stock. Walleye Capital LLC increased its position in shares of IVERIC bio by 15.2% in the second quarter. Walleye Capital LLC now owns 613,165 shares of the company’s stock worth $5,899,000 after purchasing an additional 81,020 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in IVERIC bio by 31.3% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,106 shares of the company’s stock worth $3,310,000 after buying an additional 82,092 shares in the last quarter. OLD Mission Capital LLC purchased a new stake in IVERIC bio in the second quarter worth approximately $125,000. Nisa Investment Advisors LLC boosted its stake in IVERIC bio by 39.9% in the second quarter. Nisa Investment Advisors LLC now owns 4,520 shares of the company’s stock worth $43,000 after buying an additional 1,290 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale boosted its stake in IVERIC bio by 48.9% in the second quarter. DekaBank Deutsche Girozentrale now owns 115,700 shares of the company’s stock worth $1,092,000 after buying an additional 38,000 shares in the last quarter.

IVERIC bio Trading Down 2.7 %

Shares of ISEE opened at $21.07 on Tuesday. IVERIC bio, Inc. has a 1-year low of $8.85 and a 1-year high of $24.33. The company has a current ratio of 13.40, a quick ratio of 13.40 and a debt-to-equity ratio of 0.18. The firm’s 50-day moving average price is $19.80 and its 200-day moving average price is $14.28. The firm has a market capitalization of $2.54 billion, a price-to-earnings ratio of -15.72 and a beta of 1.08.

Analyst Ratings Changes

ISEE has been the subject of several research reports. UBS Group initiated coverage on IVERIC bio in a research note on Tuesday, August 2nd. They issued a “buy” rating and a $20.00 target price for the company. HC Wainwright lifted their price target on IVERIC bio from $26.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, November 4th. B. Riley raised IVERIC bio from a “sell” rating to a “neutral” rating in a research note on Monday, October 17th. StockNews.com raised shares of IVERIC bio to a “sell” rating in a research note on Wednesday, October 5th. Finally, Robert W. Baird increased their price target on shares of IVERIC bio from $27.00 to $34.00 and gave the company an “outperform” rating in a research report on Wednesday, September 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, IVERIC bio has a consensus rating of “Moderate Buy” and an average price target of $26.20.

Insiders Place Their Bets

In other news, CEO Glenn Sblendorio sold 50,000 shares of the stock in a transaction that occurred on Wednesday, November 2nd. The stock was sold at an average price of $23.01, for a total value of $1,150,500.00. Following the completion of the transaction, the chief executive officer now owns 179,689 shares of the company’s stock, valued at approximately $4,134,643.89. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other IVERIC bio news, CEO Glenn Sblendorio sold 50,000 shares of the firm’s stock in a transaction on Wednesday, November 2nd. The stock was sold at an average price of $23.01, for a total transaction of $1,150,500.00. Following the completion of the transaction, the chief executive officer now owns 179,689 shares of the company’s stock, valued at $4,134,643.89. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Keith Westby sold 72,916 shares of the firm’s stock in a transaction on Tuesday, November 1st. The shares were sold at an average price of $23.92, for a total value of $1,744,150.72. Following the transaction, the chief operating officer now directly owns 69,128 shares of the company’s stock, valued at approximately $1,653,541.76. The disclosure for this sale can be found here. 2.70% of the stock is currently owned by company insiders.

IVERIC bio Company Profile

(Get Rating)

IVERIC bio, Inc, a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).

Further Reading

Want to see what other hedge funds are holding ISEE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IVERIC bio, Inc. (NASDAQ:ISEEGet Rating).

Institutional Ownership by Quarter for IVERIC bio (NASDAQ:ISEE)

Receive News & Ratings for IVERIC bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IVERIC bio and related companies with MarketBeat.com's FREE daily email newsletter.